Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Texas Biomed Enters Into a CRADA with U.S. Dept. of War to Help Protect Against Biological Threats

Published

on

Texas Biomedical Research Institute signed a cooperative research and development agreement (CRADA) with the U.S. Department of War to help protect service members and civilians from emerging and high-consequence biological threats.

The agreement with the Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), which manages the nation’s investments in chemical, biological, radiological, and nuclear (CBRN) defense diagnostics and medical countermeasures (MCMs), establishes a collaborative framework to accelerate the development, testing, and validation of medical countermeasures while strengthening national preparedness, according to Cory Hallam, PhD, professor and executive vice president of Applied Science and Innovation at Texas Biomed.

“We are proud to offer our unique scientific capabilities to support the nation’s biodefense mission,” said Hallam. “Texas Biomed excels in reducing the time between scientific insight and operational impact, which is critical for proactive preparedness and responding quickly when threats emerge.” 

Collaborative framework

The CRADA establishes a framework for Texas Biomed and CPE CBRND to collaborate on MCM projects that protect global populations, including U.S. soldiers serving at home and abroad. The agreement recognizes Texas Biomed’s operational impact capabilities, including high containment research and adherence to Good Laboratory Practice standards that support FDA regulatory requirements.

The Institute is also home to one of the nation’s seven National Primate Research Centers, offering expertise in translational studies and model development.

The CRADA framework is intended to ensure that critical resources for biological threats, whether from naturally emerging diseases or engineered risks, are continuously ready and available on demand, rather than episodically, continued Hallam.

“This is a long-term investment in resilience,” added Larry Schlesinger, MD, president and CEO of Texas Biomed. “As biological threats continue to evolve, partnerships like this are increasingly essential. Under this agreement, we have the potential to build new joint capabilities that will serve the nation not just today, but for decades to come.”

The post Texas Biomed Enters Into a CRADA with U.S. Dept. of War to Help Protect Against Biological Threats appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read